Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MESO NASDAQ:PASG NASDAQ:PCVX NASDAQ:STRO NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMESOMesoblast$14.74-0.4%$15.20$9.88▼$21.50$1.92B2.09186,933 shs100,788 shsPASGPassage Bio$4.21+3.2%$7.76$3.93▼$20.00$13.09M1.38146,228 shs105,825 shsPCVXVaxcyte$53.01+3.0%$58.41$28.64▼$65.00$7.43B1.31.35 million shs1.92 million shsSTROSutro Biopharma$40.24+1.0%$26.90$6.74▼$41.88$659.90M1.63267,329 shs236,907 shsTSHATaysha Gene Therapies$6.81+2.1%$5.07$2.06▼$7.30$1.92B1.252.98 million shs2.18 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMESOMesoblast-6.39%-5.55%+8.11%-7.21%+33.94%PASGPassage Bio-0.97%-20.16%-50.36%-57.10%-40.44%PCVXVaxcyte-9.84%-10.06%-15.18%-8.32%+77.55%STROSutro Biopharma+5.68%+8.77%+54.92%+156.64%+300.70%TSHATaysha Gene Therapies-4.44%+4.38%+45.95%+44.69%+250.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMESOMesoblast$14.74-0.4%$15.20$9.88▼$21.50$1.92B2.09186,933 shs100,788 shsPASGPassage Bio$4.21+3.2%$7.76$3.93▼$20.00$13.09M1.38146,228 shs105,825 shsPCVXVaxcyte$53.01+3.0%$58.41$28.64▼$65.00$7.43B1.31.35 million shs1.92 million shsSTROSutro Biopharma$40.24+1.0%$26.90$6.74▼$41.88$659.90M1.63267,329 shs236,907 shsTSHATaysha Gene Therapies$6.81+2.1%$5.07$2.06▼$7.30$1.92B1.252.98 million shs2.18 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMESOMesoblast-6.39%-5.55%+8.11%-7.21%+33.94%PASGPassage Bio-0.97%-20.16%-50.36%-57.10%-40.44%PCVXVaxcyte-9.84%-10.06%-15.18%-8.32%+77.55%STROSutro Biopharma+5.68%+8.77%+54.92%+156.64%+300.70%TSHATaysha Gene Therapies-4.44%+4.38%+45.95%+44.69%+250.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMESOMesoblast 2.33HoldN/AN/APASGPassage Bio 2.14Hold$13.25214.73% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0062.23% UpsideSTROSutro Biopharma 2.85Moderate Buy$40.781.34% UpsideTSHATaysha Gene Therapies 3.00Buy$11.6470.87% UpsideCurrent Analyst Ratings BreakdownLatest MESO, TSHA, PASG, PCVX, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026STROSutro Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$50.004/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$50.004/23/2026STROSutro Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$35.00 ➝ $41.004/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$21.00 ➝ $7.004/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$21.00 ➝ $7.004/21/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $15.004/21/2026PASGPassage Bio TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/21/2026PASGPassage Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$32.00 ➝ $8.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMESOMesoblast$17.20M110.94N/AN/A$4.67 per share3.16PASGPassage BioN/AN/AN/AN/A$5.90 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.75 per shareN/ASTROSutro Biopharma$102.48M6.51N/AN/A($15.43) per share-2.61TSHATaysha Gene Therapies$9.77M200.30N/AN/A$0.90 per share7.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/AN/APASGPassage Bio-$45.52M-$14.48N/AN/AN/AN/A-135.04%-60.37%5/12/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%N/ASTROSutro Biopharma-$191.09M-$26.10N/AN/AN/A-186.45%N/A-79.02%5/14/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-54.52%-39.23%N/ALatest MESO, TSHA, PASG, PCVX, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026STROSutro Biopharma-$2.7363N/AN/AN/A$8.89 millionN/A5/12/2026Q1 2026PASGPassage Bio-$2.79N/AN/AN/AN/AN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 million3/3/2026Q4 2025PASGPassage Bio-$2.19-$4.08-$1.89-$4.09N/AN/A2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMESOMesoblastN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMESOMesoblast0.101.581.41PASGPassage BioN/A2.072.07PCVXVaxcyteN/A7.497.91STROSutro BiopharmaN/A2.012.01TSHATaysha Gene Therapies0.2012.2312.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMESOMesoblast1.43%PASGPassage Bio53.48%PCVXVaxcyte96.78%STROSutro Biopharma96.99%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipMESOMesoblast18.80%PASGPassage Bio4.90%PCVXVaxcyte3.10%STROSutro Biopharma3.60%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMESOMesoblast80129.46 million105.12 millionOptionablePASGPassage Bio1303.21 million3.05 millionNo DataPCVXVaxcyte160144.40 million139.91 millionOptionableSTROSutro Biopharma24016.57 million15.97 millionOptionableTSHATaysha Gene Therapies180287.36 million276.48 millionOptionableMESO, TSHA, PASG, PCVX, and STRO HeadlinesRecent News About These CompaniesTaysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysisMay 7 at 7:09 PM | seekingalpha.comTaysha Gene Therapies Q1 Earnings Call HighlightsMay 7 at 3:23 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsMay 6 at 3:27 PM | marketbeat.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6 at 8:00 AM | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Here's What HappenedMay 5 at 3:39 PM | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on WednesdayMay 2, 2026 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comTaysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay RevealedApril 22, 2026 | quiverquant.comQTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Should You Buy?April 22, 2026 | marketbeat.comTaysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago LevelsApril 22, 2026 | insidermonkey.comTaysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)April 16, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month High - Still a Buy?April 16, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 9% - Should You Buy?April 15, 2026 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesApril 15, 2026 | marketbeat.comThis is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buyApril 14, 2026 | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sells $892,000.00 in StockApril 14, 2026 | insidertrades.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 SharesApril 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Wall Street Loves TJX, But Is the Stock Still a Good Deal for Investors?By Jennifer Ryan Woods | May 3, 2026Hilton’s Q1 Report Put One Big Question Front and Center for 2026By Chris Markoch | April 30, 2026MarketBeat Week in Review – 04/27 - 05/01By MarketBeat Staff | May 2, 2026MESO, TSHA, PASG, PCVX, and STRO Company DescriptionsMesoblast NASDAQ:MESO$14.74 -0.06 (-0.41%) Closing price 04:00 PM EasternExtended Trading$14.74 0.00 (0.00%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Passage Bio NASDAQ:PASG$4.21 +0.13 (+3.19%) Closing price 04:00 PM EasternExtended Trading$4.34 +0.13 (+3.09%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Vaxcyte NASDAQ:PCVX$53.01 +1.53 (+2.97%) Closing price 04:00 PM EasternExtended Trading$53.00 0.00 (-0.01%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Sutro Biopharma NASDAQ:STRO$40.24 +0.41 (+1.03%) Closing price 04:00 PM EasternExtended Trading$41.05 +0.81 (+2.01%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Taysha Gene Therapies NASDAQ:TSHA$6.81 +0.14 (+2.10%) Closing price 04:00 PM EasternExtended Trading$6.84 +0.03 (+0.37%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
